Skip to content

US · BCAX · BIOTECHNOLOGY

Bicara Therapeutics Inc. Common Stock (BCAX) intrinsic value and stock valuation

$8.44as of 2026-11-21 · Mkt cap 1.42B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bicara Therapeutics Inc. Common Stock DCF and intrinsic value

InvestorsCraft values BCAX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BCAX’s statements →

Bicara Therapeutics Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02116 bicara.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-137.95M
20222025
Free cash flow
-$-107.11M
20222025
Total equity
$401.5M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-155.6M-$-82.39M-$-39.89M-$-37.66M
Net income-$-137.95M-$-68M-$-51.98M-$-37.84M
EPSd-$-2.52M-$-1.25M-$-1M-$-731.07K
Operating cash flow-$-106.83M-$-74.75M-$-45.63M-$-32.08M
Capital expenditure-$-280K-$-70K-$-590K-$-190K
Free cash flow-$-107.11M-$-74.82M-$-46.21M-$-32.27M
Total assets$431M$569.2M$234M$6.7M
Total debt$1.71M$740K$660K$0.00
Net debt-$-94.97M-$-488.97M-$-229.78M-$-4.16M
Total equity$401.5M$491.9M$218.5M-$-17.28M
Cash and short-term investments$414.8M$489.7M$230.4M$4.16M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$125.1M$63.6M$30.6M$31.3M
Selling, general and administrative expenses$30.5M$18.8M$9.27M$6.34M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$155.6M$82.4M$39.9M$37.7M
Cost and expenses$155.6M$82.4M$39.9M$37.7M
Interest income$17.9M$14.6M$1.31M$0.00
Interest expense$0.00$0.00$0.00$110K
Depreciation and amortization$100K$60K$20K$10K
Ebitda-$-137.63M-$-67.75M-$-51.96M-$-37.72M
Operating income-$-155.6M-$-82.39M-$-39.89M-$-37.66M
Total other income/expenses, net$17.9M$14.6M-$-12.09M-$-190K
Income before tax-$-137.73M-$-67.81M-$-51.98M-$-37.84M
Income tax expense$220K$190K$10K$0.00
Net income-$-137.95M-$-68M-$-51.98M-$-37.84M
Weighted average shares outstanding$54.7M$54.4M$51.8M$51.8M
Weighted average diluted shares outstanding$54.7M$54.4M$51.8M$51.8M
Balance sheet
2025202420232022
Cash and short-term investments$414.8M$489.7M$230.4M$4.16M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$422.1M$502.5M$231.1M$4.98M
Property, plant and equipment, net$2.03M$840K$810K$640K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$8.94M$66.7M$2.91M$1.72M
Total assets$431M$569.2M$234M$6.7M
Accounts payable$7.79M$4.51M$3.19M$5.14M
Short-term debt$1.12M$610K$280K$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$29M$18M$15.1M$23.9M
Long-term debt$590K$130K$370K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$590K$59.3M$390K$90K
Capital lease obligations$1.71M$130K$660K$0.00
Total liabilities$29.5M$77.3M$15.5M$24M
Common stock$10K$10K$0.00$0.00
Retained earnings-$-358.97M-$-221.02M-$-153.02M-$-101.04M
Accumulated other comprehensive income (loss)$240K$0.00$0.00$0.00
Total equity$401.5M$491.9M$218.5M-$-17.28M
Total investments$318.1M$0.00$0.00$0.00
Total debt$1.71M$740K$660K$0.00
Net debt-$-94.97M-$-488.97M-$-229.78M-$-4.16M
Cash flow statement
2025202420232022
Net income-$-137.95M-$-68M-$-51.98M-$-37.84M
Depreciation and amortization$410K$60K$20K$10K
Stock-based compensation$15M$7.4M$1.9M$810K
Change in working capital$14.8M-$-14.13M-$-9.62M$4.95M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$0.00$2.64M$0.00$0.00
Net cash provided by operating activities-$-106.83M-$-74.75M-$-45.63M-$-32.08M
Investments in property, plant and equipment-$-280K-$-70K-$-590K-$-190K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-318.45M-$-10K-$-590K-$-190K
Common stock issued$32.3M$332.4M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$32.3M$334M$272.5M$31.7M
Net change in cash-$-393.03M$259.3M$226.3M-$-570K
Cash at end of period$96.7M$489.7M$230.4M$4.16M
Operating cash flow-$-106.83M-$-74.75M-$-45.63M-$-32.08M
Capital expenditure-$-280K-$-70K-$-590K-$-190K
Free cash flow-$-107.11M-$-74.82M-$-46.21M-$-32.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bicara Therapeutics Inc. Common Stock

        Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

        CEO
        Claire Mazumdar Clemon
        Employees
        103
        Beta
        -0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Bicara Therapeutics Inc. Common Stock (BCAX)?

        InvestorsCraft does not currently publish an intrinsic value for BCAX. How the IC value is calculated.

        Is BCAX undervalued?

        InvestorsCraft does not publish an undervaluation signal for BCAX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.